Short Interest in BR Biopharma, Inc. (NASDAQ:BRBI) Grows By 50.9%

Key Points

• Short interest rose 50.9% to 3,543 shares as of August 14, equivalent to 4.8 days of average trading volume; however, shorted shares still represented 0.0% of outstanding stock.
• BR Biopharma received a consensus “Sell” rating from analysts, while Weiss Ratings upgraded the stock from “sell (e)” to “sell (d-).”
• The stock gained 8.4% to $10.75 during Tuesday trading, while Acuitas Investments disclosed a new 3,000-share position. The company’s $0.57 annualized dividend yields 5.3%, but its payout ratio is an unusually high 625%.

BR Biopharma, Inc. (NASDAQ:BRBI - Get Free Report) saw a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 3,543 shares, a growth of 50.9% from the July 30th total of 2,348 shares. Based on an average trading volume of 742 shares, the days-to-cover ratio is presently 4.8 days. Currently, 0.0% of the company's shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised BR Biopharma from a "sell (e)" rating to a "sell (d-)" rating in a research note on Thursday, June 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, BR Biopharma presently has a consensus rating of "Sell".

Institutional Trading of BR Biopharma

A hedge fund recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC bought a new stake in BR Biopharma, Inc. (NASDAQ:BRBI - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 3,000 shares of the company's stock, valued at approximately $45,000. BR Biopharma accounts for 3.2% of Acuitas Investments LLC's holdings, making the stock its 7th largest holding.

BR Biopharma Trading Up 8.4%

NASDAQ BRBI traded up $0.83 during trading hours on Tuesday, hitting $10.75. 107 shares of the company's stock were exchanged, compared to its average volume of 958. The firm has a 50-day moving average of $10.84. BR Biopharma has a 1-year low of $9.09 and a 1-year high of $67.01. The stock has a market cap of $126.96 million and a price-to-earnings ratio of 133.81.

BR Biopharma (NASDAQ:BRBI - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.09 earnings per share (EPS) for the quarter. The business had revenue of $25.13 million during the quarter.

BR Biopharma Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 4th. Stockholders of record on Monday, August 17th will be issued a dividend of $0.1415 per share. The ex-dividend date is Monday, August 17th. This represents a $0.57 annualized dividend and a dividend yield of 5.3%. BR Biopharma's dividend payout ratio is currently 625.00%.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source